Screener
ImmunityBio, Inc. IBRX Reportable Segment — Income Tax Expense (Benefit)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of derivative liabilities | 1,108 | 5,578 |
| Other expense, net | (5,917) | (41) |
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interests | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
| Net loss attributable to ImmunityBio common stockholders | $(632,782) | $(129,646) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — income tax expense (benefit)?
- ImmunityBio, Inc. (IBRX) reported reportable segment — income tax expense (benefit) of $9K in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — income tax expense (benefit) changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — income tax expense (benefit) increased by 103.8% year-over-year, from -$234K to $9K.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — income tax expense (benefit)?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — income tax expense (benefit) has grown at a 83.7% compound annual growth rate (CAGR), from -$40K to -$135K.
- What does reportable segment — income tax expense (benefit) mean?
- This metric reflects the income tax expense or benefit specifically allocated to a reportable business segment. It captures the tax implications of the segment's financial results based on the company's internal tax allocation policies or jurisdictional tax requirements. Understanding this helps investors isolate the tax burden associated with specific business activities versus the consolidated corporate tax rate.
Ask your AI about ImmunityBio, Inc.'s reportable segment — income tax expense (benefit).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude